UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,897	09/22/2006	Peter Wisdom Atadja	33310A	7190

1095 7590 01/31/2011

NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 101/2
EAST HANOVER, NJ 07936-1080

EXAMINER	
PURDY, KYLE A	

ART UNIT	PAPER NUMBER
1611	

MAIL DATE	DELIVERY MODE
01/31/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Applicants arguments filed 1/19/2011 regarding the rejection of claim 25 made by the Examiner under 35 USC 103(a) over Remiszewski in view of Verner and Griffin have been fully considered but they are not found persuasive and are **MAINTAINED** for the reasons of record in the office action mailed on 10/19/2010.

In regards to the 103(a) rejection, Applicant asserts the following:

A) The instant claim is allowable and not obvious over the cited references.

One would have been motivated to do so because Vernier suggests that HDAIs may be combined with other agents to treat AML and therefore one would have combined an HDAI (e.g. Compound 200) as taught by Remiszewski with another agent such as an FLT-3 inhibitor (e.g. Midostaurin) as taught by Griffin to treat AML since both classes of drugs are used to treat AML, as evidenced by the teaching of Vernier and Griffin. ((Cf. In re Kerkhoven, 626 F.2d 848, 205 USPQ 1069 (CCPA 1980). Besides, Griffin teach that AML is associated with deregulated FLT-3 and therefore one would expect that the combination of an HDAI (e.g. Compound 200) as taught by Remiszewski with an FLT-3 inhibitor (e.g. Midostaurin) as taught by Griffin would also be effective in treating AML.